Evofem Biosciences, Inc. (EVFM) Research

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.

Market snapshot

Symbol
EVFM
Price
$0.01
Day change
+2.27%
Market cap
$1.2M
P/E ratio
-0.20x
52-week range
0.001-0.02
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$66.25

Peer companies

  • Biocure Technology Inc. (BICTF)
  • Bionoid Pharma, Inc. (BINP)
  • Biora Therapeutics, Inc. (BIOR)
  • Body and Mind Inc. (BMMJ)
  • Bio-Path Holdings, Inc. (BPTH)
  • Chia Tai Enterprises International Limited (CAIHF)
  • Certive Solutions Inc. (CTVEF)
  • International Stem Cell Corporation (ISCO)

Recent insider activity

  • Zhang Yan — S-Sale (104 shares) on 2024-01-12
  • Kamdar Kim P. — S-Sale (10 shares) on 2023-12-21
  • File Justin J. — trade (0 shares) on 2022-12-31
  • PELLETIER SAUNDRA L — D-Return (50000 shares) on 2022-12-31
  • Zhang Yan — trade (0 shares) on 2023-04-13

Open Evofem Biosciences, Inc. (EVFM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.